跳至主要内容
临床试验/NCT00142155
NCT00142155已完成不适用

Correlation of Fc Gamma RIIIA Receptor Expression and Response to Rituximab and Other Monoclonal Antibodies in Patients With Waldenstrom's Macroglobulinemia

Dana-Farber Cancer Institute2 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2002年1月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
300
试验地点
2

研究概览

简要总结

The purpose of this study is to determine if the type of Fc gamma RIIIa receptor that a particular patient's immune cells possess influences how they respond to rituximab and other monoclonal antibodies.

详细描述

  • A medical data collection survey sheet will be filled out by the patient or doctor with medical information pertaining to how the patient responded to rituximab and other monoclonal antibodies for use in this study.
  • Blood work will be performed to analyze the blood by molecular technology to find the kind of Fc gamna RIIIa receptor the patient possess and correlate these findings with the outcome of treatment with rituximab or other monoclonal antibodies.

研究设计

研究类型
Interventional

入排标准

年龄范围
30 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients treated with rituximab or other monoclonal antibodies for Waldenstrom's macroglobulinemia

排除标准

  • 未提供

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验

Correlation of FC Gamma RIIIA Receptor Response in... | 临床试验